Statin therapy and atrial fibrillation: Systematic review and updated meta-analysis of published randomized controlled trials

Current Opinion in Cardiology

Volumn 28, Issue 1, 2013, Pages 7-18

  Fauchier, Laurent ^a,b   Clementy, Nicolas ^a,b   Babuty, Dominique ^a,b  

^a SERVICE DE DERMATOLOGIE   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

atrial fibrillation; statin; systematic review

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TIROFIBAN;

ANTIARRHYTHMIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG UTILIZATION; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; META ANALYSIS; POSTOPERATIVE COMPLICATION; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ATRIAL FIBRILLATION; CONFIDENCE INTERVALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ODDS RATIO; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK ASSESSMENT; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84871627732     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32835b0956     Document Type: Review

References (47)

1. Kostapanos MS, Liberopoulos EN, Goudevenos JA, et al. Dostatins have an antiarrhythmic activity? Cardiovasc Res 2007; 75:10-20.
2. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369-2429.
3. Fauchier L, Pierre B, de Labriolle A, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008; 51:828-835. (Pubitemid 351255618)
4. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: Primary prevention. Europace 2011; 13:308-328.
5. White HD, Simes RJ, Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000; 343:317-326. (Pubitemid 30616697)
6. Tveit A, Grundtvig M, Gundersen T, et al. Analysis of pravastatin toprevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004; 93:780-782. (Pubitemid 38338579)
7. Schwartz GG, Olsson AG, Chaitman B, et al. Effect of intensive statin treatment on the occurrence of atrial fibrillation after acute coronary syndrome: an analysis of the MIRACL trial. Circulation 2004; 110 (Suppl):S740.
8. ChelloM, Patti G, Candura D, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 2006; 34:660-667.
9. Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 2006; 97:1490-1493.
10. Patti G, ChelloM, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery. Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study. Circulation 2006; 114:1455-1461.
11. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005; 150:1064.
12. Macfarlane PW, Norrie J, WOSCOPS Executive Committee. The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study. J Electrocardiol 2007; 40:101-109. (Pubitemid 44958596)
13. Tsai CT, Lai LP, Hwang JJ, et al. Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrial-based or dualchamber pacemaker: a prospective randomized trial. Am Heart J 2008; 156:65-70.
14. MannacioVA, IorioD, De Amicis V, et al. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg 2008; 136:1541-1548.
15. Song YB, On YK, Kim JH, et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery. Am Heart J 2008; 156:373; e9-e16.
16. Caorsi C, Pineda F, Munoz C. Pravastatin immunomodulates IL-6 and C-reactive protein, but not IL-1 and TNF-alpha, in cardio-pulmonary bypass. Eur Cytokine Netw 2008; 19:99-103.
17. TamayoE, Alvarez FJ, AlonsoO, et al. Effects of simvastatin on systemic inflammatory responses after cardiopulmonary bypass. J Cardiovasc Surg (Torino) 2009; 50:687-694.
18. Almroth H, Ho? glund N, Boman K, et al. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur Heart J 2009; 30:827-833.
19. Maggioni AP, Fabbri G, Lucci D, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J 2009; 30:2327-2336.
20. Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment toPrevent Heart Attack Trial). J Am Coll Cardiol 2009; 54:2023-2031.
21. Ji Q, Mei Y, Wang X, et al. Effect of preoperative atorvastatin therapy on atrial fibrillation following off-pump coronary artery bypass grafting. Circ J 2009; 73:2244-2249.
22. Xia W, Yin Z, Li J, et al. Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol 2009; 32:1562-1566.
23. Negi S, Shukrullah I, Veledar E, et al. Statin Therapy for the Prevention of Atrial Fibrillation Trial (SToP AF trial). J Cardiovasc Electrophysiol 2011; 22:414-419.
24. SpadaccioC, Pollari F, Casacalenda A, et al. Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study. J Cardiovasc Pharmacol 2010; 55:30-38.
25. Baran C, Durdu S, Dalva K, et al. Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: a randomized, controlled trial. Stem Cell Rev 2011. [Epub ahead of print]
26. Demir K, Can I, Koc F, et al. Atorvastatin given prior toelectrical cardioversion does not affect the recurrence of atrial fibrillation in patients with persistent atrial fibrillation whoare on antiarrhythmic therapy. Med Princ Pract 2011; 20:464-469.
27. Macfarlane PW, Murray H, Sattar N, et al. The incidence and risk factors for new onset atrial fibrillation in the PROSPER study. Europace 2011; 13:634-639.
28. Schwartz GG, Chaitman BR, Goldberger JJ, Messig M. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Am Heart J 2011; 161:993-999.
29. Sun Y, Ji Q, Mei Y, et al. Role of preoperative atorvastatin administration in protection against postoperative atrial fibrillation following conventional coronary artery bypass grafting. Int Heart J 2011; 52:7-11.
30. Peña JM, MacFadyen J, Glynn RJ, Ridker PM. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J 2012; 33:531-537.
31. Bang CN, Greve AM, Boman K, et al. Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Am Heart J 2012; 163:690-696.
32. Suleiman M, Koestler C, Lerman A, et al. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double-blind, placebo-controlled, randomized trial. Heart Rhythm 2012; 9:172-178.
33. Schmermund A, Achenbach S, Budde T, et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation 2006; 113:427-437. (Pubitemid 43803205)
34. McLean DS, Ravid S, Blazing M, et al. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat toZocor (A toZ) trials. Am Heart J 2008; 155:298-302.
35. Kourliouros A, Valencia O, Hosseini MT, et al. Preoperative high-dose atorvastatin for prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. J Thorac Cardiovasc Surg 2011; 141:244-248.
36. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12. (Pubitemid 26120810)
37. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: Wiley; 1981.
38. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-748.
39. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188. (Pubitemid 17189972)
40. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560. (Pubitemid 37088507)
41. Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291:1720-1729. (Pubitemid 38489894)
42. Rahimi K, Emberson J, McGale P, et al. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 2011; 342:d1250. doi: 10.1136/bmj. d1250.
43. Fauchier L, de Groote P. Atrial fibrillation and renin-angiotensin- aldosterone system: believe it or not. Europace 2011; 13:297-298.
44. Baigent C, Keech A, Kearney PM, et al., Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
45. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999; 353:118-119. (Pubitemid 29088085)
46. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106:1447-1452.
47. Dickersin K, Chan S, Chalmers TC, et al. Publication bias and clinical trials. Control Clin Trials 1987; 8:343-353. (Pubitemid 18040816)